Gefitinib-d6 |
Katalog-Nr.GC47395 |
Gefitinib-d6 (ZD1839-d6) ist das mit Deuterium bezeichnete Gefitinib. Gefitinib (ZD1839) ist ein potenter, selektiver und oral aktiver EGFR-Tyrosinkinase-Inhibitor mit einem IC50 von 33 nM. Gefitinib hemmt selektiv das EGF-stimulierte Tumorzellwachstum (IC50 von 54 nM) und blockiert die EGF-stimulierte EGFR-Autophosphorylierung in Tumorzellen. Gefitinib induziert auch Autophagie. Gefitinib hat AntitumoraktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1228664-49-0
Sample solution is provided at 25 µL, 10mM.
Gefitinib-d6 is intended for use as an internal standard for the quantification of gefitinib by GC- or LC-MS. Gefitinib is a selective EGFR-TK inhibitor that blocks the growth of GEO colon cancer, ZR-75-1 and MCF-10A Ha-ras breast cancer, and OVCAR-3 ovarian cancer cell lines with IC50s ranging between 0.2-0.4 µM.1 By interfering with the intracellular kinase domain, gefitinib prevents EGFR autophosphorylation and prevents downstream signal transduction. Formulations containing gefitinib were previously used to treat advanced (or recurrent) non-small cell lung cancer. However, the FDA retracted its general approval when a phase III trial failed to demonstrate an overall survival benefit.2 Formulations containing gefitinib appear to be most efficacious in treating certain EGFR gene mutations prevalent in Asian populations.3,4
1.Ciardiello, F., Caputo, R., Bianco, R., et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitorClin. Cancer Res.6(5)2053-2063(2000) 2.Gerber, D.E.EGFR inhibition in the treatment of non-small cell lung cancerDrug Dev. Res.69(6)359-372(2008) 3.Yang, C.T., Hung, J.Y., Lai, C.L., et al.Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern TaiwanKaohsiung J. Med. Sci.26(1)1-7(2010) 4.Uruga, H., Kishi, K., Fujii, T., et al.Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: A retrospective analysisIntern. Med.49(2)103-107(2010)
Average Rating: 5
(Based on Reviews and 16 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *